Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells

Katerina Dvorakova, Claire M. Payne, Margaret E Tome, Margaret M Briehl, Miguel A. Vasquez, Caroline N. Waltmire, Amy Coon, Robert T Dorr

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Imexon is an aziridine-containing iminopyrrolidone with selective growth-inhibitory potency for multiple myeloma. Our previous research indicates that imexon induces mitochondrial alterations, oxidative stress, and apoptosis. This drug represents an interesting model drug with a nonmyelosuppressive profile to study the basic mechanisms leading to antitumor activity and resistance. The major purpose of this study was to characterize an imexon-resistant RPMI8226/I cell line that was developed from RPMI8226 cells by continuous exposure to imexon. No significant differences were observed in the sensitivity to several cytotoxic drugs, including mitoxantrone, mitomycin C, melphalan, methotrexate, cytarabine, cisplatin, vincristine, and paclitaxel, in the imexon-resistant cells. However, RPMI8226/I cells were cross-resistant to arsenic trioxide, doxorubicin, fluorouracil, etoposide, irinotecan, and especially IFN-α. The data from DNA microarray and Western blot analyses indicated that the levels of antiapoptotic proteins Bcl-2 and thioredoxin-2, which reside mainly in the mitochondria, are increased in RPMI8226/I cells. In addition, increased levels of lung resistance protein were detected in imexon-resistant cells. Expression of Pglycoprotein was not detected in RPMI8226/I cells. No loss of mitochondrial membrane potential or increase in the levels of reactive oxygen species was observed in RPMI8226/I cells after exposure to imexon; however, the levels of glutathione are increased in the RPMI8226/I cells. Transmission electron microscopy revealed significant changes in the mitochondrial morphology of RPMI8226/I cells, whereas no ultrastructural changes were observed in other cellular compartments. Imexon-resistant RPMI8226/I myeloma cells appear to have a unique mechanism of resistance that is associated with morphological alterations of mitochondria, increased protection against oxidative stress, elevated levels of glutathione, and enhanced expression of antiapoptotic mitochondrial proteins.

Original languageEnglish (US)
Pages (from-to)185-195
Number of pages11
JournalMolecular Cancer Therapeutics
Volume1
Issue number3
StatePublished - Jan 2002

Fingerprint

irinotecan
Glutathione
Mitochondria
Oxidative Stress
4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one
Pharmaceutical Preparations
Mitoxantrone
Thioredoxins
Melphalan
Mitochondrial Membrane Potential
Mitochondrial Proteins
Cytarabine
Mitomycin
Vincristine
Etoposide
Oligonucleotide Array Sequence Analysis
Multiple Myeloma
Transmission Electron Microscopy
Methotrexate
Fluorouracil

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Drug Discovery
  • Pharmacology

Cite this

Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. / Dvorakova, Katerina; Payne, Claire M.; Tome, Margaret E; Briehl, Margaret M; Vasquez, Miguel A.; Waltmire, Caroline N.; Coon, Amy; Dorr, Robert T.

In: Molecular Cancer Therapeutics, Vol. 1, No. 3, 01.2002, p. 185-195.

Research output: Contribution to journalArticle

Dvorakova, K, Payne, CM, Tome, ME, Briehl, MM, Vasquez, MA, Waltmire, CN, Coon, A & Dorr, RT 2002, 'Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells', Molecular Cancer Therapeutics, vol. 1, no. 3, pp. 185-195.
Dvorakova, Katerina ; Payne, Claire M. ; Tome, Margaret E ; Briehl, Margaret M ; Vasquez, Miguel A. ; Waltmire, Caroline N. ; Coon, Amy ; Dorr, Robert T. / Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. In: Molecular Cancer Therapeutics. 2002 ; Vol. 1, No. 3. pp. 185-195.
@article{5ee0d1ada30c466f914e63985047b7a0,
title = "Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells",
abstract = "Imexon is an aziridine-containing iminopyrrolidone with selective growth-inhibitory potency for multiple myeloma. Our previous research indicates that imexon induces mitochondrial alterations, oxidative stress, and apoptosis. This drug represents an interesting model drug with a nonmyelosuppressive profile to study the basic mechanisms leading to antitumor activity and resistance. The major purpose of this study was to characterize an imexon-resistant RPMI8226/I cell line that was developed from RPMI8226 cells by continuous exposure to imexon. No significant differences were observed in the sensitivity to several cytotoxic drugs, including mitoxantrone, mitomycin C, melphalan, methotrexate, cytarabine, cisplatin, vincristine, and paclitaxel, in the imexon-resistant cells. However, RPMI8226/I cells were cross-resistant to arsenic trioxide, doxorubicin, fluorouracil, etoposide, irinotecan, and especially IFN-α. The data from DNA microarray and Western blot analyses indicated that the levels of antiapoptotic proteins Bcl-2 and thioredoxin-2, which reside mainly in the mitochondria, are increased in RPMI8226/I cells. In addition, increased levels of lung resistance protein were detected in imexon-resistant cells. Expression of Pglycoprotein was not detected in RPMI8226/I cells. No loss of mitochondrial membrane potential or increase in the levels of reactive oxygen species was observed in RPMI8226/I cells after exposure to imexon; however, the levels of glutathione are increased in the RPMI8226/I cells. Transmission electron microscopy revealed significant changes in the mitochondrial morphology of RPMI8226/I cells, whereas no ultrastructural changes were observed in other cellular compartments. Imexon-resistant RPMI8226/I myeloma cells appear to have a unique mechanism of resistance that is associated with morphological alterations of mitochondria, increased protection against oxidative stress, elevated levels of glutathione, and enhanced expression of antiapoptotic mitochondrial proteins.",
author = "Katerina Dvorakova and Payne, {Claire M.} and Tome, {Margaret E} and Briehl, {Margaret M} and Vasquez, {Miguel A.} and Waltmire, {Caroline N.} and Amy Coon and Dorr, {Robert T}",
year = "2002",
month = "1",
language = "English (US)",
volume = "1",
pages = "185--195",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells

AU - Dvorakova, Katerina

AU - Payne, Claire M.

AU - Tome, Margaret E

AU - Briehl, Margaret M

AU - Vasquez, Miguel A.

AU - Waltmire, Caroline N.

AU - Coon, Amy

AU - Dorr, Robert T

PY - 2002/1

Y1 - 2002/1

N2 - Imexon is an aziridine-containing iminopyrrolidone with selective growth-inhibitory potency for multiple myeloma. Our previous research indicates that imexon induces mitochondrial alterations, oxidative stress, and apoptosis. This drug represents an interesting model drug with a nonmyelosuppressive profile to study the basic mechanisms leading to antitumor activity and resistance. The major purpose of this study was to characterize an imexon-resistant RPMI8226/I cell line that was developed from RPMI8226 cells by continuous exposure to imexon. No significant differences were observed in the sensitivity to several cytotoxic drugs, including mitoxantrone, mitomycin C, melphalan, methotrexate, cytarabine, cisplatin, vincristine, and paclitaxel, in the imexon-resistant cells. However, RPMI8226/I cells were cross-resistant to arsenic trioxide, doxorubicin, fluorouracil, etoposide, irinotecan, and especially IFN-α. The data from DNA microarray and Western blot analyses indicated that the levels of antiapoptotic proteins Bcl-2 and thioredoxin-2, which reside mainly in the mitochondria, are increased in RPMI8226/I cells. In addition, increased levels of lung resistance protein were detected in imexon-resistant cells. Expression of Pglycoprotein was not detected in RPMI8226/I cells. No loss of mitochondrial membrane potential or increase in the levels of reactive oxygen species was observed in RPMI8226/I cells after exposure to imexon; however, the levels of glutathione are increased in the RPMI8226/I cells. Transmission electron microscopy revealed significant changes in the mitochondrial morphology of RPMI8226/I cells, whereas no ultrastructural changes were observed in other cellular compartments. Imexon-resistant RPMI8226/I myeloma cells appear to have a unique mechanism of resistance that is associated with morphological alterations of mitochondria, increased protection against oxidative stress, elevated levels of glutathione, and enhanced expression of antiapoptotic mitochondrial proteins.

AB - Imexon is an aziridine-containing iminopyrrolidone with selective growth-inhibitory potency for multiple myeloma. Our previous research indicates that imexon induces mitochondrial alterations, oxidative stress, and apoptosis. This drug represents an interesting model drug with a nonmyelosuppressive profile to study the basic mechanisms leading to antitumor activity and resistance. The major purpose of this study was to characterize an imexon-resistant RPMI8226/I cell line that was developed from RPMI8226 cells by continuous exposure to imexon. No significant differences were observed in the sensitivity to several cytotoxic drugs, including mitoxantrone, mitomycin C, melphalan, methotrexate, cytarabine, cisplatin, vincristine, and paclitaxel, in the imexon-resistant cells. However, RPMI8226/I cells were cross-resistant to arsenic trioxide, doxorubicin, fluorouracil, etoposide, irinotecan, and especially IFN-α. The data from DNA microarray and Western blot analyses indicated that the levels of antiapoptotic proteins Bcl-2 and thioredoxin-2, which reside mainly in the mitochondria, are increased in RPMI8226/I cells. In addition, increased levels of lung resistance protein were detected in imexon-resistant cells. Expression of Pglycoprotein was not detected in RPMI8226/I cells. No loss of mitochondrial membrane potential or increase in the levels of reactive oxygen species was observed in RPMI8226/I cells after exposure to imexon; however, the levels of glutathione are increased in the RPMI8226/I cells. Transmission electron microscopy revealed significant changes in the mitochondrial morphology of RPMI8226/I cells, whereas no ultrastructural changes were observed in other cellular compartments. Imexon-resistant RPMI8226/I myeloma cells appear to have a unique mechanism of resistance that is associated with morphological alterations of mitochondria, increased protection against oxidative stress, elevated levels of glutathione, and enhanced expression of antiapoptotic mitochondrial proteins.

UR - http://www.scopus.com/inward/record.url?scp=0036052593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036052593&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 185

EP - 195

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -